JP2020520956A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020520956A5 JP2020520956A5 JP2019564510A JP2019564510A JP2020520956A5 JP 2020520956 A5 JP2020520956 A5 JP 2020520956A5 JP 2019564510 A JP2019564510 A JP 2019564510A JP 2019564510 A JP2019564510 A JP 2019564510A JP 2020520956 A5 JP2020520956 A5 JP 2020520956A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- ngf
- neurotrophin
- composition
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 17
- 102000007072 Nerve Growth Factors Human genes 0.000 claims description 7
- 206010011878 Deafness Diseases 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 6
- 231100000888 hearing loss Toxicity 0.000 claims 4
- 230000010370 hearing loss Effects 0.000 claims 4
- 208000016354 hearing loss disease Diseases 0.000 claims 4
- 239000010419 fine particle Substances 0.000 claims 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229920002674 hyaluronan Polymers 0.000 claims 2
- 229960003160 hyaluronic acid Drugs 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims 1
- 108090000742 Neurotrophin 3 Proteins 0.000 claims 1
- 102100029268 Neurotrophin-3 Human genes 0.000 claims 1
- 102000003683 Neurotrophin-4 Human genes 0.000 claims 1
- 108090000099 Neurotrophin-4 Proteins 0.000 claims 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims 1
- 206010061373 Sudden Hearing Loss Diseases 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 239000002360 explosive Substances 0.000 claims 1
- 229960004584 methylprednisolone Drugs 0.000 claims 1
- 229940032018 neurotrophin 3 Drugs 0.000 claims 1
- 229940097998 neurotrophin 4 Drugs 0.000 claims 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 1
- 229960005205 prednisolone Drugs 0.000 claims 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 1
- 150000003431 steroids Chemical group 0.000 claims 1
- 238000010171 animal model Methods 0.000 description 2
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 101001111439 Homo sapiens Beta-nerve growth factor Proteins 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 210000003477 cochlea Anatomy 0.000 description 1
- 210000003027 ear inner Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 102000046917 human NGF Human genes 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17172659.9A EP3406259A1 (en) | 2017-05-24 | 2017-05-24 | Neurotrophins for use in the treatment of hearing loss |
| EP17172659.9 | 2017-05-24 | ||
| PCT/EP2018/063310 WO2018215414A1 (en) | 2017-05-24 | 2018-05-22 | Neurotrophins for use in the treatment of hearing loss |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020520956A JP2020520956A (ja) | 2020-07-16 |
| JP2020520956A5 true JP2020520956A5 (https=) | 2021-08-12 |
Family
ID=58772736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019564510A Pending JP2020520956A (ja) | 2017-05-24 | 2018-05-22 | 聴力損失の治療における使用のためのニューロトロフィン |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20200155647A1 (https=) |
| EP (2) | EP3406259A1 (https=) |
| JP (1) | JP2020520956A (https=) |
| KR (1) | KR20200011951A (https=) |
| CN (1) | CN110691607A (https=) |
| AU (1) | AU2018274589A1 (https=) |
| BR (1) | BR112019024504A2 (https=) |
| CA (1) | CA3062744A1 (https=) |
| IL (1) | IL270701A (https=) |
| RU (1) | RU2019137430A (https=) |
| WO (1) | WO2018215414A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4093387A4 (en) * | 2020-01-24 | 2024-04-24 | Dompé farmaceutici S.p.A. | GROWTH FACTOR FORMULATION FOR A CONDITION ASSOCIATED WITH AN OTIC EVENT |
| WO2022221351A1 (en) * | 2021-04-13 | 2022-10-20 | Dompé Farmaceutici S.P.A. | Treatment of neuropathic corneal pain with ngf |
| PL4452267T3 (pl) * | 2021-12-23 | 2025-06-23 | Cilcare Dev | Pochodne 4-fenylo-tetrahydropirydyny do leczenia chorób słuchu |
| EP4316505A1 (en) * | 2022-08-05 | 2024-02-07 | Dompé farmaceutici S.p.a. | Intranasal administration of ngf for the treatment of sensorineural hearing loss |
| KR102851394B1 (ko) * | 2022-11-11 | 2025-09-04 | 단국대학교 천안캠퍼스 산학협력단 | 광반응성 하이드로젤을 이용한 분화유도인자 탑재 나노캡슐 |
| EP4501346A1 (en) * | 2023-08-04 | 2025-02-05 | Dompe' Farmaceutici S.P.A. | Method for the prevention of hearing loss induced by a platinum-based chemotherapy drug |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6225282B1 (en) * | 1996-01-05 | 2001-05-01 | Genentech, Inc. | Treatment of hearing impairments |
| US5929041A (en) * | 1996-02-23 | 1999-07-27 | Amgen Inc. | Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product |
| US6113947A (en) * | 1997-06-13 | 2000-09-05 | Genentech, Inc. | Controlled release microencapsulated NGF formulation |
| ES2213861T3 (es) | 1998-10-09 | 2004-09-01 | Scil Proteins Gmbh | Procedimiento de obtencion de ngf-beta activa. |
| US7700111B2 (en) * | 2002-01-17 | 2010-04-20 | The Regents Of The University Of Michigan | Auditory nerve protection and re-growth |
| WO2009062149A1 (en) * | 2007-11-08 | 2009-05-14 | Creighton University | Methods for maintaining inner ear neurons |
| CN104203264B (zh) | 2011-12-19 | 2018-08-28 | 瓦克化学有限公司 | 新型proNGF突变体及其在生产β-NGF中的用途 |
| EP3328440A4 (en) * | 2015-07-28 | 2019-01-16 | Otonomy, Inc. | TREATMENT WITH REDUCED TRK-B AND TRK-C ANTAGONISTS |
| CA2993645A1 (en) * | 2015-07-28 | 2017-02-02 | Otonomy, Inc. | Trkb or trkc agonist compositions and methods for the treatment of otic conditions |
-
2017
- 2017-05-24 EP EP17172659.9A patent/EP3406259A1/en not_active Withdrawn
-
2018
- 2018-05-22 KR KR1020197035948A patent/KR20200011951A/ko not_active Ceased
- 2018-05-22 WO PCT/EP2018/063310 patent/WO2018215414A1/en not_active Ceased
- 2018-05-22 US US16/615,201 patent/US20200155647A1/en not_active Abandoned
- 2018-05-22 CA CA3062744A patent/CA3062744A1/en active Pending
- 2018-05-22 CN CN201880033628.8A patent/CN110691607A/zh active Pending
- 2018-05-22 JP JP2019564510A patent/JP2020520956A/ja active Pending
- 2018-05-22 BR BR112019024504-9A patent/BR112019024504A2/pt not_active IP Right Cessation
- 2018-05-22 EP EP18725242.4A patent/EP3630159A1/en not_active Withdrawn
- 2018-05-22 RU RU2019137430A patent/RU2019137430A/ru unknown
- 2018-05-22 AU AU2018274589A patent/AU2018274589A1/en not_active Abandoned
-
2019
- 2019-11-17 IL IL270701A patent/IL270701A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020520956A5 (https=) | ||
| Geschwind et al. | Defective HSV-1 vector expressing BDNF in auditory ganglia elicits neurite outgrowth: model for treatment of neuron loss following cochlear degeneration | |
| Jia et al. | Molecular and cellular mechanisms of loss of residual hearing after cochlear implantation | |
| US20210236450A1 (en) | Methods and Compositions for Preventing and Treating Auditory Dysfunctions | |
| US20210228619A1 (en) | Method Of Treating, Reducing, Or Alleviating A Medical Condition In A Patient | |
| US12048733B2 (en) | Method of treatment | |
| EP3406259A1 (en) | Neurotrophins for use in the treatment of hearing loss | |
| EP3678666A1 (en) | Specific akt3 activator and uses thereof | |
| KR20200108873A (ko) | 성장 인자 귀 제제 | |
| JP2020535131A5 (https=) | ||
| Pollack et al. | Ultrastructure of Bruch's membrane after krypton laser photocoagulation: II. Repair of Bruch's membrane and the role of macrophages | |
| IT201600081929A1 (it) | Uso del surnatante di lactobacillus paracasei nel trattamento della congiuntivite, in particolare della vernal cheratocongiuntivite | |
| JP2017523240A (ja) | 感音性難聴の治療用のステロール誘導体の利用及び対応する組成物 | |
| US10350220B2 (en) | Methods and materials for reducing suppression of immune function | |
| TWI310312B (en) | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of macular degeneration | |
| JP2021512164A5 (https=) | ||
| Havenith et al. | Local delivery of brain-derived neurotrophic factor on the perforated round window membrane in Guinea pigs: a possible clinical application | |
| JP2002503687A (ja) | 内耳の疾患又は機能障害の治療方法 | |
| WO2006128190B1 (en) | Compositions and methods for treatment of neural disorders using transforming growth factor-beta superfamily proteins and their antagonists | |
| Worsøe et al. | Intratympanic steroid prevents long-term spiral ganglion neuron loss in experimental meningitis | |
| TW202327585A (zh) | 用來抑制或預防內耳性聽力損失之含有麥角硫醇之組成物 | |
| KR20210001938A (ko) | 허피스 감염증 마우스 모델의 제조방법 | |
| TWI858583B (zh) | 組成物於製備用於預防或治療聽力缺損的藥物的用途 | |
| JPH09301891A (ja) | 眼軸長制御剤、近視または遠視の予防および治療剤 | |
| KR102453996B1 (ko) | Escrt1의 형성이 감소 또는 억제된 수지상세포 및 이의 용도 |